Skip to main content

Table 5 Cox-regression models assessing the potential of clinical and epigenetics variables in the prediction of disease-specific survival in cohort #1

From: Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients

Disease-specific survival Variable Hazard ratio (HR) 95% CI for OR P value
Multivariable Clinical stage
 III/IV 9.637 2.597–35.763 0.001
Panel #1: miR-34b/c
 Promoter methylation > P75 3.843 1.268–11.649 0.017
Clinical stage
 III/IV 8.334 2.274–30.548 0.001
Panel #2
 Promoter methylation > P75 3.786 1.038–13.810 0.044
  1. HR hazard ratio